2023 annual financial data
Rigel Pharmaceuticals 2023 Net income growth
Direct answer
Net income growth was 57.16%.
Operating income was -20,491,000 USD and net income was -25,091,000 USD.
Operating cash flow was -5,743,000 USD.
Get free Rigel Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 116,882,000 USD
- Operating income
- -20,491,000 USD
- Net income
- -25,091,000 USD
- Operating cash flow
- -5,743,000 USD